


## Brand-name Pharmaceutical Industry Investment in Research and Development



Source: *Patented Medicine Prices Review Board Annual Report, 1994*

Announcements of new capital investments by major pharmaceutical companies operating in Canada include the following:

- Astra Pharma Inc.** has invested \$150 million (1993-97) in a new Montreal research centre specializing in pain control drugs.
- Ciba-Geigy Canada** will triple its production for the North American, European and Australian markets by 1998.
- Eli Lilly Canada Inc.** broke ground in April 1995 on a \$25-million research and development centre at its headquarters in Scarborough, Ontario. The new facility will house the company's expanded Medical Division, along with the Lilly Analytical Research Laboratory. Space is also being provided for a new Bioanalytical Research Laboratory to conduct blood plasma analysis on new compounds in clinical trials. This lab will feature four state-of-the-art mass spectrometers developed and manufactured in Canada.
- Glaxo Canada Inc.** spent \$150 million (1993-97) in new administration and manufacturing facilities in Ontario.
- Merck Frosst Canada Inc.** poured \$50 million (1993) into the modernization of its Quebec manufacturing facility to produce selected drugs for domestic and export markets.